Length of hospitalization and mortality for bleeding during treatment with warfarin, dabigatran, or rivaroxaban
نویسندگان
چکیده
منابع مشابه
Length of hospitalization and mortality for bleeding during treatment with warfarin, dabigatran, or rivaroxaban
BACKGROUND Different outcomes among patients hospitalized for bleeding after starting anticoagulation could influence choice of anticoagulant. We compared length of hospitalization, proportion of Intensive Care Unit (ICU) admissions, ICU length of stay, and 30- and 90-day mortality for adults with atrial fibrillation hospitalized for bleeding after starting warfarin, dabigatran, or rivaroxaban....
متن کاملManagement and Outcomes of Major Bleeding during Treatment with Dabigatran or Warfarin
Coagulation Unit, Hematology Center, Karolinska University Hospital and Karolinska Institute, Stockholm, Sweden; Dept of Medicine, Soonchunhyang University Gumi’s Hospital, North Kyungsang Province, South Korea; McMaster University, Population Health Research Institute, Hamilton, ON, Canada; Lankenau Medical Center, Thomas Jefferson Medical College, Wynnewood, PA; Uppsala Clinical Research Cent...
متن کاملBleeding risk with dabigatran, rivaroxaban, warfarin, and antiplatelet agent in Asians with non-valvular atrial fibrillation
It is not understood if dabigatran or rivaroxaban are superior to antiplatelet agents (AA) for safety outcomes in Asians with non-valvular atrial fibrillation (NVAF). In this study we evaluated the bleeding risk of dabigatran, rivaroxaban, warfarin and AA in Asians with NVAF. This national retrospective cohort study analyzed 6,600, 3,167, 5,338 and 8,238 consecutive NVAF patients taking dabigat...
متن کاملComparative risk of gastrointestinal bleeding with dabigatran, rivaroxaban, and warfarin: population based cohort study
OBJECTIVE To determine the real world risk of gastrointestinal bleeding associated with the use of the novel oral anticoagulants dabigatran and rivaroxaban compared with warfarin. DESIGN Retrospective, propensity matched cohort study. SETTING Optum Labs Data Warehouse, a large database including administrative claims data on privately insured and Medicare Advantage enrollees. PARTICIPANTS...
متن کاملLetter by Hifumi et al regarding article, "Management and outcomes of major bleeding during treatment with dabigatran or warfarin".
BACKGROUND The aim of this study was to compare the management and prognosis of major bleeding in patients treated with dabigatran or warfarin. METHODS AND RESULTS Two independent investigators reviewed bleeding reports from 1034 individuals with 1121 major bleeds enrolled in 5 phase III trials comparing dabigatran with warfarin in 27 419 patients treated for 6 to 36 months. Patients with maj...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: PLOS ONE
سال: 2018
ISSN: 1932-6203
DOI: 10.1371/journal.pone.0193912